Vertex Pharmaceuticals scored a major win Tuesday with the release of data from three clinical trials testing three different triple combinations of cystic fibrosis drugs. Patients genetically ...

Vertex Pharmaceuticals Incorporated (Nasdaq: ... While there are many different types of CFTR mutations that can cause the disease, ... Restoring CFTR function leads to lower levels of SwCl.

Vertex Pharmaceuticals ... While there are many different types of CFTR mutations that can ... The defective function and/or absence of CFTR protein results in poor flow of salt and water into ...

Waltham, Massachusetts-based Sionna is developing CF drugs that target NBD1, a domain on the CFTR protein. NBD1 has long been thought to be important for normalizing CFTR function because it’s ...

-Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

May 1 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage ...

July 18 (Reuters) - Vertex Pharmaceuticals Inc Skip to main content Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv ...

VX-880 is a stem-cell-derived islet cell replacement therapy that Vertex picked up in September 2019 in its $950 million Semma Therapeutics buyout. The therapy won a fast-track tag from the FDA in ...

Synspira, which launched on Thursday with $8 million in financing, says it is looking for office space in the Boston area. California-based Synedgen has spun out its experimental cystic fibrosis ...